Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies
Tomonori Araki,Machiko Kawahira,Mototsugu Shimokawa,Taiga Otsuka,Kohei Hayashi,Yuki Sonoda,Takuya Honda,Kazuhiko Nakao,Taro Shibuki,Junichi Nakazawa,Shiho Arima,Masaru Fukahori,Keisuke Miwa,Futa Koga,Yujiro Ueda,Yoshihito Kubotsu,Akitaka Makiyama,Hozumi Shimokawa,Shigeyuki Takeshita,Kazuo Nishikawa,Azusa Komori,Satoshi Otsu,Ayumu Hosokawa,Tatsunori Sakai,Hisanobu Oda,Shuji Arita,Hiroki Taguchi,Kengo Tsuneyoshi,Yasunori Kawaguchi,Toshihiro Fujita,Takahiro Sakae,Kenta Nio,Yasushi Ide,Norio Ureshino,Tsuyoshi Shirakawa,Toshihiko Mizuta,Kenji Mitsugi
DOI: https://doi.org/10.1159/000542137
2024-10-19
Oncology
Abstract:Introduction: Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improve overall survival (OS) and progression-free survival (PFS) in patients with pancreatic cancer, compared with gemcitabine (GEM). However, whether PFS is a surrogate marker of OS in pancreatic cancer chemotherapy focusing on FOLFIRINOX or GEM plus nab-paclitaxel remains unknown. We aimed to verify whether PFS can be a surrogate marker of OS in prognosis prediction. Methods: This was an integrated analysis of the NAPOLEON study and retrospective cohort of the NAPOLEON-2 study - a multicenter observational study conducted in Japan, using real-world data. The primary and secondary endpoints were OS and PFS, respectively. The correlation between OS and PFS in first- and second-line treatments was assessed using Method of Moments estimation. An analysis was performed in patients with confirmed OS at the end of follow-up. The NAPOLEON-2 cohort included only patients who received 5-fluorouracil, leucovorin, and nanoliposomal irinotecan (NFF) as second-line treatment. Results: Among 479 patients, the correlation between PFS and OS from first- and second-line chemotherapies was calculated in 310 and 225 patients, respectively. The R-squared values for the correlation between PFS and OS from first- and second-line chemotherapies were 0.74 and 0.76, respectively. There was no statistically significant difference in first-line treatment between the FOLFIRINOX and GEM plus nab-paclitaxel groups (p = 0.92). Therefore, the FOLFIRINOX group may not have shown a stronger correlation than the NFF group. Conclusion: PFS can be a surrogate marker of OS in first- and second-line therapies. Appropriate prognostic estimation might contribute to proper treatment selection.